Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with Chemotherapy for Relapsed/Refractory CBF AML in Children
NCT02680951Phase 1Withdrawn
- Sponsor
- Emory University
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label trial of dasatinib in acute myeloid leukemia (AML) (3 arms), sponsored by Emory University. Primary endpoints: Number of Adverse Events up to 161 Days, Number of Dose-Limiting Toxicities up to 42 Days and 1 more. Planned start Dec 2015; status: withdrawn.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02680951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680951.